Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
October 23, 2024 09:00 ET
|
Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals Featured on CBS in San Francisco
February 28, 2019 09:15 ET
|
Adial Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for...
Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option
February 26, 2019 08:00 ET
|
Adial Pharmaceuticals, Inc.
Proceeds from Offering Expected to Fully Fund Initial Phase 3 Trial of AD04 CHARLOTTESVILLE, Va., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage...
Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
February 21, 2019 08:45 ET
|
Adial Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for...
Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial’s AD04 for its Phase 3 Trial
February 20, 2019 09:00 ET
|
Adial Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of...
Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse
February 15, 2019 08:30 ET
|
Adial Pharmaceuticals, Inc.
Continuation patent would allow for broader protection beyond claims protected under current patents CHARLOTTESVILLE, Va., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....
Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder
February 12, 2019 09:33 ET
|
Adial Pharmaceuticals, Inc.
Distinguished Professor Markus Heilig joins an accomplished assemblage of addiction specialists including Dr. Giovanni Addolorato and Professors Hannu Alho, Tomas Zima and Sebastian Mueller ...
Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award
February 07, 2019 09:15 ET
|
Adial Pharmaceuticals, Inc.
Dr. Johnson Recognized for Advancing Scientific Understanding of Alcoholism and its Prevention CHARLOTTESVILLE, Va., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;...
Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder
February 01, 2019 09:20 ET
|
Adial Pharmaceuticals, Inc.
Scheduled to appear today on KSWB-TV FOX 5 Morning News in San Diego at 10:40 AM ET/7:40 AM PT Additional appearance scheduled on KPIX-TV (CBS-CW) “Bay Area Focus” morning show February 3rd during...
Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants
January 24, 2019 08:30 ET
|
Adial Pharmaceuticals, Inc.
Enhances Balance Sheet; Funds to be Utilized for Phase 3 Clinical Trial of AD04 CHARLOTTESVILLE, Va., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW)...